Research activity
Multicenter and international clinical trials and research roles.
Roles & research centres
Key research roles and affiliated research centres.
European Society of Hypertension (ESH)
Working Group on Small Arteries — Core Member, Section of Sexual Dysfunction
Aristotle University, Thessaloniki, Greece.
Researcher in Sexual Dysfunction
Excellence Center of the European Society of Hypertension, 2nd Propedeutic Department of Internal Medicine, Hippokration General Hospital of Thessaloniki / AUTH.
Researcher in Secondary Hypertension
Excellence Center of the European Society of Hypertension, 2nd Propedeutic Department of Internal Medicine, Hippokration General Hospital of Thessaloniki / AUTH.
International multicenter studies
Major multicenter and international clinical studies.
ZEUS
Ziltivekimab versus placebo in patients with established ASCVD, chronic kidney disease and systemic inflammation. Participation as Investigator at AUTH.
NCT05021835
VICTORION-1 PREVENT
Inclisiran versus placebo for prevention of major cardiovascular events in high-risk individuals without a prior ASCVD event. Participation as Investigator.
NCT05739383
STRIDE
Semaglutide in people with type 2 diabetes mellitus and peripheral arterial disease, assessing functional and cardiovascular outcomes.
BAX / Baxdrostat programme
Clinical research programme investigating aldosterone synthase inhibition with baxdrostat in uncontrolled and resistant arterial hypertension.
BaxDuo programme
Studies of baxdrostat plus dapagliflozin in chronic kidney disease and hypertension, with renal and cardiovascular endpoints.
PREVENT-HF
Baxdrostat + dapagliflozin versus dapagliflozin for prevention of new-onset heart failure and cardiovascular death. Participation as Investigator.
NCT06677060
Novo Nordisk NN9388-7700
CagriSema versus semaglutide, cagrilintide and placebo in CKD, type 2 diabetes and overweight/obesity.
BAX-24
Baxdrostat versus placebo in resistant arterial hypertension, with assessment of 24-hour ambulatory blood pressure. Participation as Investigator.
NCT06168409
REvive
Redasemtide (S-005151) versus placebo in acute ischemic stroke. Participation as Investigator.
NCT05953480
MRXC-302
Contezolid acefosamil/contezolid versus linezolid for moderate or severe diabetic foot infection. Participation as Investigator.
EUCT 2022-500257-16-00
ORION-16
Inclisiran versus placebo in adolescents with heterozygous familial hypercholesterolemia. Participation as Investigator.
NCT04652726
ITHACA
Complement C3 inhibitor AMY-101 versus placebo in severe COVID-19/ARDS. Participation as Investigator.
EudraCT 2020-004408-32
SAVE-MORE
suPAR-guided anakinra versus placebo in COVID-19 pneumonia. Participation as Investigator.
NCT04680949
ESH ABPM COVID-19 Study
International multicenter observational ambulatory blood pressure monitoring study of blood-pressure control and hypertension phenotypes during the COVID-19 period.
PMID 39248094
WAYLIVRA PASS / WAY4001
Multicenter non-interventional post-authorisation safety study and long-term registry of volanesorsen (Waylivra) in familial chylomicronaemia syndrome.
EUPAS36702 · Study ID 47815
Novo Nordisk NNC0194-0499 / NN9500-7730 — NASH / ALD
Single research entry for the NNC0194-0499 programme with semaglutide, cagrilintide and placebo in NASH and alcohol-related liver disease. Participation as Investigator.
NCT05016882 · NCT06409130
Scientific activity
Hellenic Atherosclerosis Society — Hypertension Working Group
Working Group Member.
European Society of Hypertension — Working Group on Small Arteries
Core Member, Section Sexual Dysfunction.
ESH ABPM COVID-19 Study
Investigator in the international research group. Full publication in Journal of Hypertension · DOI 10.1097/HJH.0000000000003752
Cardiovascular Medicine Fellowship — Washington, DC
Advanced training at Georgetown University and Veterans Affairs Medical Center (VAMC).
Hellenic Atherosclerosis Society — Metabolic Syndrome and Prediabetes Working Group
Working Group Member.